Skip to Content
Discovering the causes of cancer and the means of prevention

Gladys M. Glenn, M.D. Ph.D.

Information for Journalists

To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:


Phone: 301-496-6641

Gladys M. Glenn, M.D. Ph.D.

Gladys M. Glenn, M.D. Ph.D.

Organization:National Cancer Institute
Division of Cancer Epidemiology & Genetics, Genetic Epidemiology Branch
Address:NCI Shady Grove
Room 6E546


Dr. Glenn received an M.D. in 1976 and a Ph.D. in Molecular Biology in 1979, from the University of Pennsylvania School of Medicine and Graduate School, respectively. She completed her Medical Internship and Internal Medicine Residency in 1982 at Thomas Jefferson Hospital in Philadelphia, PA. Her Oncology Fellowship training from 1982-1984 was at the Johns Hopkins Oncology Center in Baltimore. In 1984, she joined the National Cancer Institute’s Laboratory of Immunobiology. While there, she began molecular biology investigations with her colleagues that led to identification of the von Hippel-Lindau disease gene, the first of several hereditary kidney cancer susceptibility genes identified later by this group of multidisciplinary associates.

During this time, Dr. Glenn was credentialed at the NIH Clinical Center and became a co-investigator on the Urologic Malignancy Protocol of the Urologic Oncology Branch of Surgery at NCI. Dr. Glenn began combining her laboratory work with her screening clinic. For a period of eighteen years, her activities included service as the primary physician for comprehensive clinical diagnostic screening of hundreds of at-risk individuals from families affected by von Hippel-Lindau syndrome, as well as linkage analyses and gene cloning for VHL, BHD, MET (HPRC) and FH (HLRCC). For a six-year period after joining the NCI Cancer Diagnosis Branch, Dr. Glenn continued clinical investigative screenings of hereditary kidney cancers. Here she served as both a Medical and Project Officer, and received the Public Health Service Special Achievement Award. In 1996, Dr. Glenn expanded her clinical investigations of cancer genetics when she joined the Family Studies Section of the Genetic Epidemiology Branch. She continues as physician and clinical genetic investigator in the screening clinic for new cases of hereditary kidney cancer syndromes and genodermatoses cases in family investigations for associated internal malignancies.

Research Interests

  • Epidemiologic studies of factors that affect development and growth of benign and malignant neoplasms of von Hippel-Lindau disease (n >500 participants).
  • Genodermatoses and kidney cancer in Birt-Hogg-Dubé Syndrome and Hereditary Leiomyomatoses and Renal Cell Cancer (>80 kindreds)
  • Phenotype/Genotype correlations in kindreds with mutations in the VHL, MET, BHD, and FH genes.